Oncogenic activation of the WNT/b-catenin signaling pathway is common in hepatocellular carcinoma (HCC). Dishevelled (Dvl), a key activator of the pathway, inhibits the adenomatous polyposis coli complex, and this leads to the accumulation of b-catenin and promotes tumorigenesis. Recently, a novel inhibitor of Dishevelled, namely Dapper (Dpr), was isolated in Xenopus. To explore whether HDPR1, the human homologue of Dpr, has an anti-oncogenic role in hepatocarcinogenesis, we studied the expression of this gene in HCCs. We found that there were two alternatively spliced transcripts of HDPR1, designated as a and b forms, in human liver. Downregulation of the gene expression was observed in 31 (43%) of the 72 human HCC samples using the primer pair that amplified both transcripts. Furthermore, the HDPR1a was downregulated in 42 (58%) of 72 human HCCs and the downregulation significantly correlated with accumulation of b-catenin. Also, downregulation of HDPR1 by RNA interference in HLE cells led to cytoplasmic accumulation of b-catenin. Furthermore, a CpG island located at the promoter region and exon 1 of the HDPR1 gene was methylated in 22 (51%) of human HCCs. We showed that downregulation of HDPR1, in hepatoma cell lines, was associated with methylation of this CpG island using bisulfite sequencing and 5-aza-2 0 -deoxycytidine demethylation experiment. In addition to methylation-mediated downregulation of HDPR1, allelic loss (13-28% of informative cases) was detected using microsatellite markers flanking the HDPR1 locus. To conclude, downregulation of HDPR1 is common in HCCs, frequently involves hypermethylation of the promoter region, and allelic loss of the HDPR1 locus may also play a role.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide (Llovet et al., 2003) . The molecular mechanisms contributing to hepatocarcinogenesis are largely unknown. It has been shown that activation of the WNT/b-catenin signaling pathway is commonly associated with the development of HCC, colorectal cancer and various types of cancer (for a review, see Polakis, 2000; Giles et al., 2003) .
In the absence of WNT ligands, glycogen synthase kinase 3 beta (GSK-3b) in the adenomatous polyposis coli (APC) complex phosphorylates b-catenin, and this leads to the ubiquitination and degradation of b-catenin by the ubiquitin-proteasome system. Hence, the b-catenin is maintained at a low level. When WNT ligands are present, the ligands bind to the transmembrane receptors Frizzled (Fz) , and the signal is transduced to cytoplasmic protein Dishevelled (Dvl) by phosphorylation. Activated Dvl inhibits the APC complex, and b-catenin therefore accumulates. Subsequently, b-catenin enters the nucleus, forms complex with members of T-cell factor/lymphoid-enhancing factor (TCF/LEF) and upregulates TCF/LEF-dependent transcription of target genes such as c-MYC (He et al., 1998) and cyclin D1 (Shtutman et al., 1999; Tetsu and McCormick, 1999) .
Molecules involved in the WNT/b-catenin pathway are affected in cancers (for a review, see Polakis, 2000; Giles et al., 2003) . Mutations of AXIN (Satoh et al., 2000; Taniguchi et al., 2002) , APC (Munemitsu et al., 1995) and CTNNB1 itself (de la Coste et al., 1998; Miyoshi et al., 1998) have been shown to result in accumulation of b-catenin. Recently, Dvl overexpression has been demonstrated in mesothelioma and nonsmall-cell lung cancer (Uematsu et al., 2003a, b) , and the overexpression is correlated with accumulation of b-catenin. These results suggest Dvl is a key activator of the pathway and may enhance oncogenesis.
The Xenopus Dapper (Dpr) protein is a novel Dvl-binding partner identified in a yeast two-hybrid screening (Cheyette et al., 2002) . The C-terminus of Dpr, designated as PDZ-binding (PDZ-B) domain, binds to the PDZ domain of Dvl (Cheyette et al., 2002 , Wong et al., 2003 . It has been shown that Dpr inhibits Dvl function during Xenopus embryogenesis. Also, Dpr downregulates Wnt ligand-mediated transcription and reduces the level of b-catenin accumulation through inhibition of Dvl in cell culture system (Cheyette et al., 2002) . However, how Dpr exerts its function in WNT/bcatenin signaling remains to be elucidated. One possible answer is that Dpr stabilizes GSK-3b and Axin in the APC complex as shown by coimmunoprecipitation (Cheyette et al., 2002) . Another possibility is that Dpr competes with Fz for binding to PDZ domain of Dvl, blocks signal transduction to Dvl, and hence inhibits Dvlmediated stabilization of b-catenin (Wong et al., 2003) .
We have previously demonstrated overexpression of b-catenin, in membranous, cytoplasmic and/or nuclear compartments, in 41 (68%) of 60 HCCs (Wong et al., 2001) . However, the molecular mechanism leading to this overexpression has not been investigated. Since Dpr is a negative regulator of Dvl, we hypothesize that deregulation of Dpr may contribute to the overexpression of b-catenin observed in HCC.
In the present study, we describe the identification of alternatively spliced transcripts, namely the a and b forms, of HDPR1 gene, the human homologue of Dpr. We studied the mRNA expression levels of these transcripts in human HCCs, and demonstrated that HDPR1 was frequently (43%) downregulated in human HCCs. Also, we provided evidence that, in hepatoma cell lines and HCCs, the downregulation was associated with hypermethylation of CpG island spanning the promoter and exon 1 of HDPR1.
Results

Alternatively spliced transcripts of HDPR1 gene
We performed RT-PCR using a pair of primers, p1 and p4b, that was specific to exon 1 and exon 4 of the HDPR1 gene, to check whether the gene was expressed in normal human liver (Figure 1a) . The RT-PCR produced two fragments, 523 and 412 bp in size (Figure 1b) . We cloned the two fragments and checked the DNA sequences (data not shown). The two fragments were specific to the HDPR1 gene and were two alternatively spliced transcripts. We named these transcripts the a and b forms. The a form corresponds to the HDPR1 mRNA sequence originally described by Cheyette et al. (2002; GenBank Accession no. BK000256 ). The b form, which has not been described previously, is the same as the a form, except that 111 bp (GenBank Accession no. AY603415) of the 5 0 end of exon 4 is spliced out (Figure 1a ).
HDPR1 mRNA expression is frequently downregulated in human HCCs
In order to study the expression level of HDPR1 mRNA using RT-PCR, we designed primers that could produce a single fragment for analysis. Two primer pairs were designed, and one of them, p2 and p4a, could amplify the a form only and produced a single 358 bp fragment (Figure 1) . The other pair, p2 and p3, could amplify both the a and b forms and produce a single 257 bp fragment. The expression levels of HDPR1 in 72 human HCCs and their corresponding nontumorous livers were studied. In 42 (58%) HCCs, the HDPR1a mRNA expression level was downregulated by more than two folds when compared with those of their corresponding nontumorous livers (Figure 2a) . Downregulation was also observed in 31 (43%) of the 72 HCC samples using the primer pair that amplified both transcripts. We also examined the expression level of three hepatoma cell lines including BEL7402, HepG2 and HLE. It was found that the HDPR1 mRNA expression level of HLE was comparable to that of normal human livers (Figure 2b ), whereas those of the other two cell lines, BEL7402 and HepG2, were relatively reduced. Among these cell lines, BEL7402 had the lowest expression level of HDPR1 mRNA.
Hypermethylation of HDPR1 promoter region in human HCCs and HCC cell lines
In silico analysis of the HDPR1 genomic region showed the presence of a CpG island located at the promoter region and exon 1 of the HDPR1 gene. Since hypermethylation of promoter CpG island is a common epigenetic mechanism which downregulates gene expression, we performed methylation-sensitive PCR MS-PCR) to examine the methylation status of the CpG island. For BEL7402, we detected only the methylation-specific PCR product but not the unmethylation-specific one (Figure 3a ). In contrast, only unmethylation-specific PCR product could be detected in HLE. For HepG2, both methylation and unmethylation-specific PCR products could be detected. These suggest that the CpG island is likely to be heavily methylated in BEL7402, partially methylated in HepG2 and unmethylated in HLE. These differences in the degree of methylation seemed to correlate with the expression levels observed ( Figure 2b) ; the more heavily was the CpG island methylated, the lower was the mRNA expression level. We then amplified the bisulfite-treated DNA of BEL7402, HepG2 and HLE cells, using primers suitable for bisulfite sequencing, cloned the PCR products, and performed DNA sequencing. Most of CpG dinucleotides in the clones of BEL7402 were methylated, whereas the CpG dinucleotides in the clones obtained from HLE cells were unmethylated (Figure 3b and c).
We also performed MS-PCR to investigate the methylation status of the CpG island in 43 pairs of human HCCs and their corresponding nontumorous tissues. Three other normal human liver samples were also included for MS-PCR study. Methylation of promoter CpG island was detected in 22 (51%) of the HCCs and in nine (18%) of the nontumorous tissues ( Figure 3d ). In all these nine cases of nontumorous livers, both methylation-and unmethylation-specific PCR products were present. In contrast, methylation was not detected in the normal human livers by bisulfite sequencing and MS-PCR.
We tried to correlate the downregulation of HDPR1 mRNA expression with methylation status of HDPR1 CpG island in HCCs. The nine cases, which had both methylation-specific and unmethylation-specific PCR products in the nontumorous livers, were excluded from the analysis because in this study the level of expression in HCCs was compared with that of the corresponding nontumorous livers. However, we could not establish statistically significant correlation between the downregulation of HDPR1 expression with methylation status of HDPR1 CpG island in HCCs (Table 1 ). There were cases in which the HDPR1 CpG island was methylated but the HDPR1 mRNA levels were not downregulated. This might be because MS-PCR could amplify methylation-specific PCR products even if there was a small number of cells which had methylated CpG island in a tissue sample, but the expression level in this tissue sample might not be significantly downregulated. There were also cases without methylation but the HDPR1 mRNA levels were downregulated. This suggested that other mechanisms such as loss of heterozygosity (LOH) and/or other epigenetic alteration might play a role in the downregulation of HDPR1 in HCCs.
To provide further evidence that methylation play a role in the downregulation of HDPR1 mRNA expression, we investigated whether demethylation could restore HDPR1 mRNA expression in BEL7402. We treated the cells with 5-aza-2 0 -deoxycytidine (5-Aza-dC), a demethylating agent, for 4 days at varying concentrations. The expression of HDPR1 began to increase at 0.1 mM 5-Aza-dC and reached the highest level at about 50 mM 5-Aza-dC ( Figure 4a ). As expected, 5-Aza-dC did not alter the level of HDPR1 mRNA expression in HLE (Figure 4b) . The above results support that methylation of the CpG island was present in BEL7402, downregulated the expression level of HDPR1, and was able to be reversed by 5-Aza-dC treatment.
Allelic loss at the HDPR1 locus in primary HCCs
We then investigated the status of allelic loss at the HDPR1 locus in primary HCCs. Four microsatellites marker were used; D14S980 and D14S274 were located 5 0 to HDPR1, whereas D14S1038 and D14S994 were 3 0 to HDPR1. In the 57 pairs of HCC cases examined, LOH of markers D14S980, D14S274, D14S1038 and D14S994 was found to be 19, 14, 28 and 13% of the informative cases, respectively ( Figure 5 ). LOH was not too frequent, and this answers our suggestion that LOH might play a role as another mechanism in the downregulation of HDPR1 in HCCs.
Correlation between downregulation of HDPR1a mRNA and b-catenin expression in human HCCs
We recently showed that b-catenin was overexpressed in 41 of 60 (68%) HCCs using immunohistochemistry (Wong et al., 2001) . The overexpression was seen in membranous, cytoplasmic and/or nuclear patterns. Since HDPR1 is supposed to be an inhibitor of Dvl and this inhibition maintains a low level of b-catenin in cells, we reason that downregulation of HDPR1 may be a factor leading to the accumulation of b-catenin in HCCs. We therefore examined the correlation between the HDPR1 mRNA expression levels and b-catenin expression in HCCs observed in our previous study Table 2) . We showed that downregulation of HDPR1a mRNA significantly correlated with accumulation of b-catenin in HCCs (P ¼ 0.01, Fisher exact test). However, we did not observe any significant correlation between accumulation of b-catenin and the mRNA expression of HDPR1 when both a and b forms were amplified using primers common to both forms.
Downregulation of HDPR1 leads to cytoplasmic accumulation of b-catenin
To provide further evidence that downregulation of HDPR1 mRNA correlates with accumulation of b-catenin, we performed RNA interference experiment to knockdown HDPR1 mRNA in HLE cells. To achieve this, we employed vector-based shRNA construct to establish stably transfected clones of HLE cells. In several clones, HDPR1 mRNA was successfully downregulated (Figure 6a ), and b-catenin was shown to accumulate in the cytoplasm (Figure 6b ) but not in the nucleus (Figure 6c ). Accordingly, cytoplasmic accumulation of b-catenin without nuclear accumulation did not lead to upregulation of b-catenin downstream target genes, cyclin D1 and c-MYC (Figure 6b ). Thus, we have shown that loss of HDPR1 was involved in the upregulation of b-catenin.
Discussion
WNT/b-catenin signaling pathway is important in tumorigenesis and embryogenesis. In the present study, we demonstrated that HDPR1, a novel antagonist of WNT/b-catenin signaling pathway (Cheyette et al., 2002) , was frequently and significantly downregulated at mRNA level in HCCs. Also, we showed that this downregulation was associated with methylationmediated gene silencing in HCC cells and there was frequent methylation of the promoter region in human HCCs.
It has been implicated that Dpr inhibits the Dvlmediated stabilization of b-catenin by (i) stabilizing Gsk-3 and Axin in the APC complex (Cheyette et al., 2002) and/or (ii) competing with Fz for Dvl binding (Wong et al., 2003) . Downregulation of HDPR1 by methylation may release the inhibitory effect exerted by HDPR1 on the WNT/b-catenin signaling. This then enhances the accumulation of b-catenin and promotes tumorigenesis.
We have shown that downregulation of HDPR1a, but not both a and b forms, correlated with accumulation of b-catenin in HCCs. This suggests that the functions of a and b forms may be different. The predicted amino-acid sequence of the a form has extra 37 amino acids as compared with that of the b form. To our knowledge, these 37 amino acids do not match to any known conserved functional domain in public databases. The functional roles of the a and b forms of HDPR1 need further characterization. Also, we did not observe any correlation with a particular staining pattern, that is, a particular subcellular location, of b-catenin. This suggests that the role of HDPR1a may be for maintaining the total level of b-catenin in cells. The different subcellular localization of overexpressed b-catenin observed in HCCs may be due to other factors such as loss of E-cadherin expression, nuclear accumulation of p53 and mutations of Axins and b-catenin.
A recent in silico study has also identified a human DAPPER1 gene, and the predicted protein consists of 799 amino acids (Katoh and Katoh, 2003) . However, (2002, GenBank Accession number, BK000256). Our RT-PCR results suggest that there are two alternatively spliced forms of HDPR1, and the difference in the predicted number of amino acids of these two forms is 37. This answers to the difference in the predicted number of amino acids suggested by these two groups.
As mentioned before, the total b-catenin level, irrespective of membranous, cytoplasmic and nuclear localization, is usually low in normal cells. In WNTsignal-induced cells or tumor cells, the level of b-catenin accumulates in the cell membrane and cytoplasm and may translocate to the nucleus. Prange et al. (2003) suggested that membranous accumulation probably preceded cytoplasmic accumulation of b-catenin during hepatocarcinogenesis based on their observations of immunohistochemical staining with b-catenin antibody on dysplastic nodules (DNs) and HCCs. It is believed that DNs are premalignant lesions in chronic liver disease, and they progress to HCCs upon further carcinogenic event(s) (for a review see, Theise et al., 2002) . Prange et al. (2003) found no cytoplasmic or nuclear accumulation of b-catenin or point mutations in the GSK-3b-binding site of b-catenin in any of the 25 DNs. Membranous overexpression of b-catenin was however observed in 12 (48%) of the 25 DNs studied. They also showed that loss of E-cadherin expression and nuclear accumulation of p53 correlated with nuclear accumulation of b-catenin in HCCs. Loss of E-cadherin expression and nuclear accumulation of p53 were, however, not found in DNs. Chan et al. (2002) suggested that the interaction between E-cadherin and b-catenin kept b-catenin in the membranous compartment. They showed that a mutant form of b-catenin, in which codon 45 was deleted, did not bind to E-cadherin but accumulated in cytoplasm, whereas the wild type bound to E-cadherin and was localized in cell membranes. However, it was shown that in E-cadherin-negative tumors, the expression of b-catenin was highly heterogeneous and membranous staining was found in most of these cases (Wei et al., 2002) . It was suggested that other members of the cadherin family might sequester b-catenin in the membrane. From the observations, it is reasonable to suggest that overexpression of cytoplasmic and membranous b-catenin is a distinct event which occurs before nuclear accumulation of b-catenin. Upon mutations of b-catenin and/or members of the APC complex, cytoplasmic and membranous b-catenin will translocate to the nucleus. This suggestion may however need further evidence to substantiate.
The above observations in DNs and HCCs also suggest that the deregulation of the WNT/b-catenin signaling pathway in hepatocarcinogenesis happens in different stages. The overexpression of b-catenin may first be sequestered to the membranous compartment by E-cadherin and/or other proteins; during hepatocarcinogenesis, loss of E-cadherin releases membranous b-catenin; it then translocates and accumulates in the cytoplasm, and may subsequently enter the nucleus if there are suitable signals such as mutations of b-catenin and Axins. These raise the question whether downregulation of HDPR1a is an early event in the deregulation of the WNT/b-catenin signaling pathway in HCCs. To answer this question, it would be necessary to test whether membranous accumulation of b-catenin in DNs is associated with downregulation of HDPR1a.
Mutations of b-catenin and/or members of the APC complex were previously supposed to be the major mechanisms in the deregulation of Wnt/b-catenin pathway in carcinogenesis. However, recent studies indicate that the deregulation might depend on more complex mechanisms, and other members of the pathway may play complementary roles. Recently, peptidyl-proplylisomerase, PIN1, a member of the pathway, has been shown to be upregulated in breast cancer (Wulf et al., 2001; Ryo et al., 2003) and HCCs (Pang et al., 2004) . In Pang et al. (2004) , it was suggested that PIN1 overexpression and mutation of b-catenin were mutually exclusive events, and they both led to accumulation of b-catenin in HCCs. It is not surprising that there will be more members of the pathway found to be deregulated in carcinogenesis in the near future.
HDPR1 also repressed the JNK signaling in cell culture (Cheyette et al., 2002) . It was shown that HDPR1 morpholino, which could knock down the expression of this gene, activated the JNK pathway as detected by AP-1-responsive reporter. They also provided evidence that inactivation of JNK signaling by HDPR1 was through inhibition of Dvl-mediated phosphorylation of c-Jun by JNK. Recent studies showed that c-Jun was involved in promoting liver tumor formation by antagonizing p53 function in apoptosis during early stages (Eferl et al., 2003) , activating cell proliferation during liver regeneration through cyclin D1 (Schwabe et al., 2003) , and upregulating matrix metalloproteinase-1 in HCC cell lines (Sugioka et al., 2004) that was implicated in stromal invasion at the early stage of HCC (Okazaki et al., 1997) . These results suggest that c-Jun plays an important role in the early development of HCC, and HDPR1 may also be involved in this early process.
In conclusion, HDPR1 mRNA expression was frequently and significantly downregulated in HCC, and this downregulation frequently involved methylation-mediated gene silencing. Allelic loss also plays a role in this downregulation. Further investigations are needed to reveal the importance of HDPR1 in tumorigenesis in the liver and other organs.
Materials and methods
Tumor samples and cell lines
A total of 70 pairs of primary HCCs and the corresponding nontumorous liver tissues from Chinese patients were studied. They were collected at the time of surgical resection at Queen Mary Hospital at the University of Hong Kong between 1992 and 2000. All of the specimens were obtained immediately after surgical resection, snap-frozen in liquid nitrogen, and kept at À701C. Hepatoma cell lines used in this study were either obtained from American Type Culture Collection (HepG2 and HLE) or Shanghai Institute of Cell Biology (BEL7402, Su et al., 1994) . They were maintained in DMEM supplemented with 10% fetal bovine serum and 100 U/ml of penicillin and streptomycin.
DNA extraction, RNA extraction and cDNA synthesis Genomic DNA was prepared by phenol-chloroform extraction after proteinase K treatment. Total RNA was extracted from human HCCs and hepatoma cell lines using Trizol reagent (Invitrogen, Tokyo) according to the manufacturer's protocol. cDNA was synthesized using GeneAmp s Gold RNA PCR Core Kit (PE Biosystems, Foster City, CA, USA).
Detection of HDPR1 mRNA expression by RT-PCR
The expression of HDPR1 mRNA was detected by RT-PCR with specific primers (Figure 1a) . Primer sequences are as follows: p1, sense, 5 0 -AGTCGCCTGGAGGA-GAAGTT-3 0 ; p2, sense, 5 0 -GCGAAGAGATGCTGGTTTGT-3 0 ; p3, antisense, 5
0 -CTGAGAGACTCAAGGTCGCC-3 0 ; p4a, antisense, 5 0 -AAATTGTGGTG-TGGAGAGGG-3 0 ; p4b, antisense, 5 0 -GAAGTGGACTGGGATAGCGA-3 0 . Primer pair p1/4b amplifies two bands; the 523 and 412 bp bands are specific to the a and b forms, respectively. Primer pair p2/4a amplifies one band, which is specific to the a form. Primer pair p2/3 is common to both forms and PCR products appear as a single band. For b-actin: sense, 5 0 -GTGGGGCGCCCCAGGCAC CA-3 0 ; and antisense, 5 0 -CTCCTTAATGTCACGCAC GATTTC-3 0 . The PCR was terminated at the exponential phases to avoid saturation; 35 and 25 cycles were used for HDPR1 and b-actin (for normalization), respectively. The conditions for hot start PCR were as follows: 951C for 12 min, followed by amplification at 941C for 30 s, 551C for 30 s, and 721C for 30 s, and a final extension at 721C for 7 min. The final RT-PCR products were resolved on 1.5% agarose gel stained with ethidium bromide and their signal intensities were measured by GelWorks 1D Intermediate Software (UVP). Downregulation of HDPR1 was taken as significant when the ratio of HDPR1 mRNA of the tumor to that of the corresponding nontumorous liver was less than two folds after normalization with b-actin.
Sodium bisulfite treatment
Sodium bisulfite treatment was carried out essentially as described by Clark et al. (1994) with minor modifications. Genomic DNA (2 mg) was denatured with 0.3 M NaOH and treated with 3.6 M sodium bisulfite (pH 5.0) at 551C for 16-20 h. Bisulfite-treated DNA was purified with Wizard DNA cleanup system (Promega, Madison, WI, USA). Purified DNA samples were desulfonated with 0.3 M NaOH at room temperature, neutralized with ammonium acetate, ethanol precipitated, and resuspended in 30 ml Tris-EDTA buffer.
Bisulfite sequencing
In total, 5 ml of bisulfite-treated DNA was subjected to PCR using the following primers: sense, 5 0 GTTTGGGAAGTGAA AGAAATTTAATT; antisense, 5 0 CTAAAACCCCAACATC CTATTACAAT. The size of PCR product is 184 bp. The reaction was carried out with the following conditions: 951C for 12 min, 40 cycles of 941C for 30 s, 551C for 30 s and 721C for 30 s, and final extension at 721C for 10 min. Amplified PCR product was purified from agarose gel and cloned into pGEM-T Easy vector (Promega). DNA sequencing was performed on at least 10 individual clones using the 377 automatic DNA sequencer (Applied Biosystems, Foster City, CA, USA).
MS-PCR
Bisulfite-treated DNA was amplified by PCR using primer pairs that were able to discriminate between methylated and unmethylated DNA of the HDPR1 gene. The primer sequences were as follows: For methylated DNA, sense, 5 0 -ACTA CTAATCAAAAACGCCCTACG-3 0 ; antisense, 5 0 -AATAGT CGTGTTTTATTTTCGGGTAC-3 0 . For unmethylated DNA, sense, 5 0 -AAAACTACTAATCAAAAACACCCTACAC-3 0 ; antisense, 5 0 -ATAGTTGTGTTTTATTTTTGGGTATGA-3 0 . The sizes of PCR products for the methylated and unmethylated DNA are 181 and 183 bp, respectively. PCR conditions: hot start at 951C for 12 min, followed by 35 cycles of 941C for 30 s, 551C for 30s, and 721C for 30 s, and final extension at 721C for 7 min.
5-Aza-dC treatment of hepatoma cell lines 2 Â 10 5 cells were seeded into six-well plates and cultured for 24 h before treatment with 5-Aza-dC (Sigma, St Louis, MO, USA), a demethylating agent. HCC cells were then treated with various concentrations, 0, 0.1, 1.0, 10, 50 and 100 mM, of 5-Aza-dC for 4 days. Total RNA was extracted from the cells, and cDNA was synthesized as described above.
LOH assay
Four fluorescent-labeled microsatellite markers were used for LOH analysis. These markers flank the HDPR1 locus; D14S980 and D14S274 locate, respectively, at 2.0 and 1.4 Mbp 5 0 to the first exon of HDPR1; whereas D14S1038 and D14S994 locate, respectively, at 0.5 and 1.6 Mbp 3 0 to the first exon of HDPR1. The markers were amplified from 50 to 100 ng DNA extracted from human HCCs and their corresponding nontumorous livers. Reaction was initiated by hot start at 951C for 12 min, 10 cycles of amplification (941C for 15 s, 551C for 15 s and 721C for 15 s), and 20 cycles of amplification with lower denaturing temperature (891C for 15 s, 551C for 15 s and 721C for 15 s) followed by a final elongation at 721C for 30 min. PCR products were then analysed on a model 377 automatic DNA sequencer (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions, and the results were analysed with Genotyper software (Applied Biosystems). Cases were defined as LOH when an allele peak signal from tumor DNA was reduced by 50% compared with their corresponding nontumorous livers.
shRNA (short hairpin RNA) constructs and establishment of stable clones ShRNA constructs, in plasmid vector pRNA-U6.1/Neo backbone, were designed and ordered from GenScript Corporation (Scotch Plains, USA). This construct will express shRNA which will specifically target to the HDPR1 mRNA (GenBank Accession number, BK000256); the target sequence: 5 0 -GAAT TCGAAACAGGCGTGT-3 0 (positions 1179-1197 of BK000256). Sequence of scrambled control: 5 0 -GAATTCGAAAGACGGCT GT-3 0 , mismatch nucleotides are underlined. HLE cells were transfected using Lipofectamine-2000 (Invitrogen, CA, USA) and selected with G418 (Invitrogen, CA, USA). Stably transfected clones were selected and established.
Western blotting analysis
Cytoplasmic and nuclear extracts were prepared as described previously (Chan et al., 2004) with some modifications. Briefly, cell monolayer was scraped in ice-cold phosphate buffer saline, and was centrifuged at 1500 r.p.m. for 5 min at 41C. The cells were resuspended in ice-cold hypotonic buffer A (10 mM HEPES (pH 7.9), 10 mM KCl, 1 mM EDTA, 1 mM dithiothreitol (DTT), 1 Â Completet (Roche, Mannheim, Germany)) with 0.5% Nonidet NP-40 (Sigma, St Louis, MO, USA). Cells were placed and swollen on ice for 1 h. Cytoplasmic protein was collected after centrifugation at 11 000 r.p.m. for 5 min at 41C. Nuclear pellets were resuspended in ice-cold buffer B (20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM DTT, 1 Â Completet) and incubated on ice for 30 min. Nuclear extract was obtained by centrifugation at 11 000 r.p.m. for 5 min at 41C. The protein concentrations were determined by Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA).
Proteins (20 mg) were separated on a 10% SDS-PAGE gel and transferred onto membranes. The following antibodies were used: mouse monoclonal anti-b-catenin (Transduction Laboratories, La Jolla, CA, USA), mouse monoclonal anti-bactin (Sigma, MO, USA), rabbit monoclonal anti-cyclin D1 (LabVision, CA, USA), mouse monoclonal anti-cMYC (sc-40, Santa Cruz, CA, USA) and rabbit polyclonal anti-topoisomerase I (sc-10783, Santa Cruz, CA, USA).
